Expression and role of microtubuleassociated protein in breast cancer

doi:10.3760/cma.j.issn.1673-422X.2016.10.015

Abstract

Abstract: In recent years, many new microtubuleassociated proteins are found or studied extensively in the treatment of breast cancer. Endbinding protein 1 (EB1) has the promotional effects on cell proliferation and enhances the carcinogenesis of breast cancer, and also can affect the chemosensitivity of the treatment. MAP7 domaincontaining protein 3 (Mdp3) expresses in breast epithelial cells and plays an important role on the growth and metastasis. Nucleolar and spindleassociated protein (NuSAP) gene is upregulated in breast cancer and is considered as a biomarker for breast cancer. Tau expression level has a strong correlation with estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor2 (HER2), and it remains controversial in the results of the effect of paclitaxel chemotherapy and hormone treatment.

Key words: Microtubuleassociated proteins, Breast neoplasms

Huang Sanqian, Li Jing, Liu Zhihong, Zeng Liang. Expression and role of microtubuleassociated protein in breast cancer[J]. Journal of International Oncology, 2016, 43(10): 783-786.

References

［1］ Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015［J］. CA Cancer J Clin, 2016, 66(2): 115132. DOI: 10.3322/caac.21338. ［2］ Tala, Xie SB, Sun XD, et al. Microtubuleassociated protein Mdp3 promotes breast cancer growth and metastasis［J］. Theranostics, 2014, 4(10): 10521061. DOI: 10.7150/thno.9727. ［3］ Sun L, Gao J, Dong X, et al. EB1 promotes AuroraB kinase activity through blocking its inactivation by protein phosphatase 2A［J］. Proc Natl Acad Sci USA, 2008, 105(20): 71537158. DOI: 10.1073/pnas.0710018105. ［4］ Luo Y, Li D, Ran J, et al. Endbinding protein 1 stimulates paclitaxel sensitivity in breast cancer by promoting its actions toward microtubule assembly and stability［J］. Protein Cell, 2014, 5(6): 469479. DOI: 10.1007/s1323801400530. ［5］ Dong X, Liu F, Sun L, et al. Oncogenic function of microtubule endbinding protein 1 in breast cancer［J］. J Pathol, 2010, 220(3): 361369. DOI: 10.1002/path.2662. ［6］董鑫. EB1调节AuroraB活性的机制及功能［D］. 天津: 南开大学, 2011. ［7］ Thomas GE, Sreeja JS, Gireesh KK, et al. +TIP EB1 downregulates paclitaxelinduced proliferation inhibition and apoptosis in breast cancer cells through inhibition of paclitaxel binding on microtubules［J］. Int J Oncol, 2015, 46(1): 133146. DOI: 10.3892/ijo.2014.2701. ［8］ Morimura S, Takahashi K. Rac1 and Stathmin but not EB1 are required for invasion of breast cancer cells in response to IGFI［J］. Int J Cell Biol, 2011, 2011: 615912. DOI: 10.1155/2011/615912. ［9］ Sauer G, Krner R, Hanisch A, et al. Proteome analysis of the human mitotic spindle［J］. Mol Cell Proteomics, 2005, 4(1): 3543. DOI: 10.1074/mcp.M400158MCP200. ［10］ Yadav S, Verma PJ, Panda D. Cterminal region of MAP7 domain containing protein 3 (MAP7D3) promotes microtubule polymerization by binding at the Cterminal tail of tubulin［J］. PLoS One, 2014, 9(6): e99539. DOI: 10.1371/journal.pone.0099539. ［11］Tala, Sun X, Chen J, et al. Microtubule stabilization by Mdp3 is partially attributed to its modulation of HDAC6 in addition to its association with tubulin and microtubules［J］. PLoS One, 2014, 9(3): e90932. DOI: 10.1371/journal.pone.0090932. eCollection 2014. ［12］Gallaud E, Caous R, Pascal A, et al. Ensconsin/map7 promotes microtubule growth and centrosome separation in drosophila neural stem cells ［J］. J Cell Biol, 2014, 204(7): 11111121. DOI: 10.1083/jcb.201311094. ［13］Cassimeris L, Spittle C. Regulation of microtubuleassociated proteins ［J］. Int Rev Cytol, 2001, 210: 163226. ［14］Raemaekers T, Ribbeck K, Beaudouin J, et al. NuSAP, a novel microtubuleassociated protein involved in mitotic spindle organization［J］. J Cell Biol, 2003, 162(6): 10171029. DOI: 10.1083/jcb.200302129. ［15］Vanden Bosch A, Raemaekers T, Denayer S, et al. NuSAP is essential for chromatininduced spindle formation during early embryogenesis［J］. J Cell Sci, 2010, 123(Pt 19): 32443255. DOI: 10.1242/jcs.063875. ［16］Davis JN, Wojno KJ, Daignault S, et al. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormoneresistant prostate cancer［J］. Cancer Res, 2006, 66(24): 1189711906. ［17］Gulzar ZG, Mckenney JK, Brooks JD. Increased expression of NuSAP in recurrent prostate cancer is mediated by E2F1［J］. Oncogene, 2013, 32(1): 7077. DOI: 10.1038/onc.2012.27. ［18］Kretschmer C, SternerKock A, Siedentopf F, et al. Identification of early molecular markers for breast cancer［J］. Mol Cancer, 2011, 10(1): 15. DOI: 10.1186/147645981015. ［19］ Chen DT, Nasir A, Culhane A, et al. Proliferative genes dominate malignancyrisk gene signature in histologicallynormal breast tissue［J］. Breast Cancer Res Treat, 2010, 119(2): 335346. DOI: 10.1007/s105490090344y. ［20］何敢, 喻嫦娥, 吴海滨, 等. NuSAP在乳腺癌中的表达及临床意义［J］. 中国普通外科杂志, 2015, 24(5): 707711. DOI: 10.3978/j.issn.10056947.2015.05.018. ［21］ Bonneau C, GurardLevin ZA, Andre F, et al. Predictive and prognostic value of the Tau protein in breast cancer［J］. Anticancer Res, 2015, 35(10): 51795184. ［22］ Andre F, Hatzis C, Anderson K, et al. Microtubule associated proteintau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptorpositive breast cancer［J］. Clin Cancer Res, 2007, 13(7): 20612067. ［23］范小庆, 熊秋云, 涂剑宏, 等. 乳腺浸润性导管癌组织中Tau蛋白表达及其与临床病理因素相关性分析［J］. 中华医学杂志, 2013, 93(16): 12581260. DOI: 10.3760/cma.j.issn.03762491.2013.16.013. ［24］ Honig A, Gehrmann M, Kranke P, et al. Microtubuleassociated protein tau correlates with estrogen receptor status but not with in vitro paclitaxel sensitivity in primary breast cancer［J］. Eur J Gynaecol Oncol, 2014, 35(5): 503507. ［25］ Koo DH, Lee HJ, Ahn JH, et al. Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2positive breast cancer［J］. Tumour Biol, 2015, 36(8): 58655871. DOI: 10.1007/s1327701532589. ［26］ Wang K, Deng QT, Liao N, et al. Tau expression correlated with breast cancer sensitivity to taxanesbased neoadjuvant chemotherapy［J］. Tumour Biol, 2013, 34(1): 3338. DOI: 10.1007/s132770120507z. ［27］ Zhou J, Qian S, Li H, et al. Predictive value of microtubuleassociated protein Tau in patients with recurrent and metastatic breast cancer treated with taxanecontaining palliative chemotherapy［J］. Tumour Biol, 2015, 36(5): 39413947. DOI: 10.1007/s1327701530377. ［28］ Won HS, Lee KE, Sung SH, et al. Topoisomerase Ⅱ alpha and microtubuleassociated proteintau as a predictive marker in axillary lymph node positive breast cancer［J］. Tumori, 2014, 100(1): 8086. DOI: 10.1700/1430.15820. ［29］ Irshad S, Gillett C, Pinder SE, et al. Assessment of microtubuleassociated protein (MAP)Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer［J］. Breast Cancer Res Treat, 2014, 144(2): 331341. DOI: 10.1007/s1054901428554.

[1]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[5]	Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58.
[6]	Wang Jing, Xu Wenting. Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526.
[7]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying. Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients [J]. Journal of International Oncology, 2023, 50(9): 527-531.
[8]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng. Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway [J]. Journal of International Oncology, 2023, 50(8): 449-456.
[9]	Pan Shulan, Liu Chang, He Ping. Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer [J]. Journal of International Oncology, 2023, 50(8): 457-462.
[10]	Wang Wende, Zeng De. Research progress on the mechanism of endocrine therapy resistance for breast cancer [J]. Journal of International Oncology, 2023, 50(6): 352-356.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong. Research progress on targeted therapy of breast cancer with low expression of HER2 [J]. Journal of International Oncology, 2023, 50(4): 236-240.
[13]	Zhou Ting, Xu Shaohua, Mei Lin. Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer [J]. Journal of International Oncology, 2023, 50(3): 144-149.
[14]	Li Lixi, Zhang Di, Luo Yang, Ma Fei. Clinical application of PARP inhibitors in breast cancer [J]. Journal of International Oncology, 2023, 50(2): 91-96.
[15]	Geng Rui, Ma Junqiang, Guo Qiang, Niu Zhaofeng. Tendency of elderly patients with breast cancer to choose comprehensive treatment mode and its influencing factors [J]. Journal of International Oncology, 2023, 50(11): 650-654.